proclarabio.comHealthcareFounded: 2006Funding to Date: $112.79MM
Developer of disease-modifying therapies intended to be used for the treatment of neurodegenerative diseases. The company's therapies develop novel therapies that recognize and target multiple misfolded proteins, enabling clinicians to make a transformative impact on the lives of patients affected by Alzheimer's, Parkinson's and systemic amyloidosis.
View Enterprise Value for Proclara Biosciences.